Do analysts recommend MEDP or STVN?

Medpace presently has a consensus target price of $584.18, suggesting a potential downside of 5.89%. Given Medpace's higher probable upside, research analysts clearly believe Medpace is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 0 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.23 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, MEDP or STVN?

Medpace has higher revenue and earnings than Stevanato Group. Medpace is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.85 $451.12M $17.06 36.39 Stevanato Group €1.34B 5.10 €158.21M €0.56 40.36

Is MEDP or STVN more profitable?

Medpace has a net margin of 17.67% compared to Stevanato Group's net margin of 10.99%. Medpace's return on equity of 110.15% beat Stevanato Group's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Stevanato Group 10.99% 10.43% 6.16%

Do analysts recommend CRL or STVN?

Charles River Laboratories International currently has a consensus price target of $255.65, suggesting a potential downside of 13.41%. Given Charles River Laboratories International's higher probable upside, analysts plainly believe Charles River Laboratories International is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Charles River Laboratories International 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.69 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Do analysts recommend STVN or RVTY?

Revvity has a consensus target price of $108.36, suggesting a potential downside of 13.23%. Given Revvity's higher possible upside, analysts plainly believe Revvity is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Revvity 0 Sell rating(s) 12 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has higher earnings & valuation, STVN or RVTY?

Revvity has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stevanato Group €1.34B 5.10 €158.21M €0.56 40.36 Revvity $2.86B 4.88 $241.20M $2.10 59.47

Do analysts recommend ICLR or STVN?

Icon presently has a consensus price target of $170.40, indicating a potential downside of 1.06%. Given Icon's higher probable upside, equities analysts plainly believe Icon is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Icon 2 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.41 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, ICLR or STVN?

Icon has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Icon $8.25B 1.60 $229.34M $4.26 40.43 Stevanato Group €1.34B 5.10 €158.21M €0.56 40.36

Is ICLR or STVN more profitable?

Stevanato Group has a net margin of 10.99% compared to Icon's net margin of 3.99%. Stevanato Group's return on equity of 10.43% beat Icon's return on equity. Company Net Margins Return on Equity Return on Assets Icon 3.99% 8.02% 4.56% Stevanato Group 10.99% 10.43% 6.16%

Do analysts prefer TECH or STVN?

Bio-Techne presently has a consensus target price of $68.92, suggesting a potential downside of 4.70%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Techne 1 Sell rating(s) 14 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.06 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Stevanato Group (STVN) Competitors

€22.60 +0.25 (+1.12%)

As of 08/21/2026 03:58 PM Eastern

Compare

STVN vs. MEDP, CRL, RVTY, ICLR, and TECH

Should you buy Stevanato Group stock or one of its competitors? Stevanato Group's main competitors and comparable companies include Medpace (MEDP), Charles River Laboratories International (CRL), Revvity (RVTY), Icon (ICLR), and Bio-Techne (TECH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Stevanato Group compare to Medpace?

Medpace (NASDAQ:MEDP) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

78.0% of Medpace shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 0.7% of Stevanato Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Medpace presently has a consensus target price of $584.18, suggesting a potential downside of 5.89%. Given Medpace's higher probable upside, research analysts clearly believe Medpace is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Medpace has a net margin of 17.67% compared to Stevanato Group's net margin of 10.99%. Medpace's return on equity of 110.15% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Stevanato Group	10.99%	10.43%	6.16%

Medpace has higher revenue and earnings than Stevanato Group. Medpace is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.85	$451.12M	$17.06	36.39
Stevanato Group	€1.34B	5.10	€158.21M	€0.56	40.36

In the previous week, Medpace had 26 more articles in the media than Stevanato Group. MarketBeat recorded 26 mentions for Medpace and 0 mentions for Stevanato Group. Medpace's average media sentiment score of 1.10 beat Stevanato Group's score of 0.00 indicating that Medpace is being referred to more favorably in the media.

Company	Overall Sentiment
Medpace	Positive
Stevanato Group	Neutral

Summary

Medpace beats Stevanato Group on 14 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

98.9% of Charles River Laboratories International shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by insiders. Comparatively, 0.7% of Stevanato Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Charles River Laboratories International has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

Stevanato Group has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.51	-$144.34M	-$4.85	N/A
Stevanato Group	€1.34B	5.10	€158.21M	€0.56	40.36

Stevanato Group has a net margin of 10.99% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Stevanato Group	10.99%	10.43%	6.16%

In the previous week, Charles River Laboratories International had 10 more articles in the media than Stevanato Group. MarketBeat recorded 10 mentions for Charles River Laboratories International and 0 mentions for Stevanato Group. Charles River Laboratories International's average media sentiment score of 0.53 beat Stevanato Group's score of 0.00 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Overall Sentiment
Charles River Laboratories International	Positive
Stevanato Group	Neutral

Charles River Laboratories International currently has a consensus price target of $255.65, suggesting a potential downside of 13.41%. Given Charles River Laboratories International's higher probable upside, analysts plainly believe Charles River Laboratories International is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Charles River Laboratories International beats Stevanato Group on 10 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Revvity?

Stevanato Group (NYSE:STVN) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Stevanato Group has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Revvity has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Revvity has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	5.10	€158.21M	€0.56	40.36
Revvity	$2.86B	4.88	$241.20M	$2.10	59.47

86.7% of Revvity shares are held by institutional investors. 0.7% of Stevanato Group shares are held by insiders. Comparatively, 0.9% of Revvity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Stevanato Group has a net margin of 10.99% compared to Revvity's net margin of 8.16%. Stevanato Group's return on equity of 10.43% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Revvity	8.16%	8.34%	5.01%

Revvity has a consensus target price of $108.36, suggesting a potential downside of 13.23%. Given Revvity's higher possible upside, analysts plainly believe Revvity is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Revvity had 10 more articles in the media than Stevanato Group. MarketBeat recorded 10 mentions for Revvity and 0 mentions for Stevanato Group. Revvity's average media sentiment score of 1.18 beat Stevanato Group's score of 0.00 indicating that Revvity is being referred to more favorably in the news media.

Company	Overall Sentiment
Stevanato Group	Neutral
Revvity	Positive

Summary

Revvity beats Stevanato Group on 11 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Icon?

Icon (NASDAQ:ICLR) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

In the previous week, Icon had 5 more articles in the media than Stevanato Group. MarketBeat recorded 5 mentions for Icon and 0 mentions for Stevanato Group. Icon's average media sentiment score of 1.57 beat Stevanato Group's score of 0.00 indicating that Icon is being referred to more favorably in the media.

Company	Overall Sentiment
Icon	Very Positive
Stevanato Group	Neutral

95.6% of Icon shares are owned by institutional investors. 44.0% of Icon shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Icon has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Icon presently has a consensus price target of $170.40, indicating a potential downside of 1.06%. Given Icon's higher probable upside, equities analysts plainly believe Icon is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Icon has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25B	1.60	$229.34M	$4.26	40.43
Stevanato Group	€1.34B	5.10	€158.21M	€0.56	40.36

Stevanato Group has a net margin of 10.99% compared to Icon's net margin of 3.99%. Stevanato Group's return on equity of 10.43% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Stevanato Group	10.99%	10.43%	6.16%

Summary

Icon beats Stevanato Group on 11 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Bio-Techne has higher earnings, but lower revenue than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.32	$181.86M	$1.15	62.89
Stevanato Group	€1.34B	5.10	€158.21M	€0.56	40.36

Bio-Techne has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Bio-Techne has a net margin of 14.97% compared to Stevanato Group's net margin of 10.99%. Bio-Techne's return on equity of 13.23% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Stevanato Group	10.99%	10.43%	6.16%

In the previous week, Bio-Techne had 16 more articles in the media than Stevanato Group. MarketBeat recorded 16 mentions for Bio-Techne and 0 mentions for Stevanato Group. Bio-Techne's average media sentiment score of 1.20 beat Stevanato Group's score of 0.00 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Overall Sentiment
Bio-Techne	Positive
Stevanato Group	Neutral

Bio-Techne presently has a consensus target price of $68.92, suggesting a potential downside of 4.70%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

99.0% of Bio-Techne shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 0.7% of Stevanato Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bio-Techne beats Stevanato Group on 13 of the 16 factors compared between the two stocks.

Get Stevanato Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STVN vs. The Competition

Export

Metric	Stevanato Group	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	€6.84B	€10.24B	€7.37B	€24.31B
Dividend Yield	N/A	1.45%	2.53%	3.70%
P/E Ratio	40.36	61.54	272.60	30.31
Price / Sales	5.10	110.99	623.83	21.00
Price / Cash	25.62	27.04	78.62	32.49
Price / Book	3.80	37.34	13.05	6.77
Net Income	€158.21M	€56.67B	€3.47B	€1.07B
7 Day Performance	6.97%	5.24%	2.09%	-0.65%
1 Month Performance	16.36%	9.02%	6.64%	3.38%
1 Year Performance	0.36%	24.45%	25.02%	14.90%

Stevanato Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STVN Stevanato Group	3.5366 of 5 stars	€22.60 +1.1%	N/A	+0.4%	€6.84B	€1.34B	40.36	6,010
MEDP Medpace	3.5581 of 5 stars	$605.50 +0.5%	$584.18 -3.5%	+33.9%	$16.90B	$2.53B	35.49	6,200	Trending News Insider Trade
CRL Charles River Laboratories International	1.8779 of 5 stars	$281.70 +1.7%	$255.65 -9.2%	+82.7%	$13.45B	$4.02B	N/A	19,700	Trending News Insider Trade
RVTY Revvity	3.3803 of 5 stars	$115.57 -0.4%	$108.36 -6.2%	+32.8%	$12.89B	$2.86B	55.03	11,000	Positive News
ICLR Icon	3.703 of 5 stars	$165.58 -0.3%	$170.40 +2.9%	-2.0%	$12.68B	$8.25B	38.87	40,100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STVN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stevanato Group (STVN) Competitors

STVN vs. MEDP, CRL, RVTY, ICLR, and TECH

How does Stevanato Group compare to Medpace?

Summary

How does Stevanato Group compare to Charles River Laboratories International?

Summary

How does Stevanato Group compare to Revvity?

Summary

How does Stevanato Group compare to Icon?

Summary

How does Stevanato Group compare to Bio-Techne?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STVN vs. The Competition

Stevanato Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stevanato Group (STVN) Competitors

STVN vs. MEDP, CRL, RVTY, ICLR, and TECH

How does Stevanato Group compare to Medpace?

Which has more volatility and risk, MEDP or STVN?

Do insiders & institutionals have more ownership in MEDP or STVN?

Do analysts recommend MEDP or STVN?

Is MEDP or STVN more profitable?

Which has higher valuation & earnings, MEDP or STVN?

Does the media favor MEDP or STVN?

Summary

How does Stevanato Group compare to Charles River Laboratories International?

Do institutionals and insiders have more ownership in CRL or STVN?

Which has more volatility & risk, CRL or STVN?

Which has preferable earnings and valuation, CRL or STVN?

Is CRL or STVN more profitable?

Does the media favor CRL or STVN?

Do analysts recommend CRL or STVN?

Summary

How does Stevanato Group compare to Revvity?

Which has more risk and volatility, STVN or RVTY?

Which has higher earnings & valuation, STVN or RVTY?

Do insiders and institutionals hold more shares of STVN or RVTY?

Is STVN or RVTY more profitable?

Do analysts recommend STVN or RVTY?

Does the media refer more to STVN or RVTY?

Summary

How does Stevanato Group compare to Icon?

Does the media favor ICLR or STVN?

Do insiders & institutionals believe in ICLR or STVN?

Which has more volatility and risk, ICLR or STVN?

Do analysts recommend ICLR or STVN?

Which has stronger earnings and valuation, ICLR or STVN?

Is ICLR or STVN more profitable?

Summary

How does Stevanato Group compare to Bio-Techne?

Which has stronger earnings and valuation, TECH or STVN?

Which has more risk & volatility, TECH or STVN?

Is TECH or STVN more profitable?

Does the media prefer TECH or STVN?

Do analysts prefer TECH or STVN?

Do insiders and institutionals hold more shares of TECH or STVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STVN vs. The Competition

Stevanato Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools